The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage

This study has been completed.
Sponsor:
Information provided by:
Aria Aesthetics Inc.
ClinicalTrials.gov Identifier:
NCT00991198
First received: October 6, 2009
Last updated: June 6, 2011
Last verified: June 2011
  Purpose

This study is an evaluation of the role of topical dissolved oxygen to lessen visible signs of photodamage using a select regimen of topical dissolved oxygen containing cosmeceutical products. Evaluation of the overall skin tolerability of topical dissolved oxygen (safety) utilizing the regimen of products.


Condition Intervention Phase
Rosacea
Acne Vulgaris
Atopic Dermatitis
Seborrheic Dermatitis
Drug: Topical oxygen
Drug: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage in Individuals With Multiple Skin Conditions A Double-Blind, Placebo Controlled Comparative Trial

Resource links provided by NLM:


Further study details as provided by Aria Aesthetics Inc.:

Primary Outcome Measures:
  • skin grading evaluation of photodamage [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • stratum corneum hydration (skin capacitance) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • bioinstrumental assessment of skin "melanin" lightening, and lesional erythematous sites [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • bioinstrumental assessment of skin texture, scaliness (desquamation) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • punch biopsy histopathologic examination (H&E, and immunohistochemistry for Aquaporin 3, and Filaggrin) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • RT-PCR collagenase , and hypoxia-inducible factor-1 alpha [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • product performance [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 49
Study Start Date: September 2009
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
Aria Regimens 0.5% conc
Drug: Topical oxygen
0.5% concentration of Topical oxygen
Experimental: B
Aria Regimen (5 products) 0.25% conc
Drug: Topical oxygen
0.25% concentration topical oxygen
Placebo Comparator: C
Aria Regimen Control without O2
Drug: placebo
no O2

  Eligibility

Ages Eligible for Study:   25 Years to 60 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must be female, 25-60 years old in good general health;
  • Subjects must be Fitzpatrick Types I, II, III, IV, V
  • Subjects must be willing to forgo the use of facial cosmetics (e.g. facial moisturizers,creams, foundations, blush, etc.) during the course of the study.
  • Subjects may ONLY use facial regimen of products provided by sponsor(lipstick, lip gloss, and eye mascara permitted).

Exclusion Criteria:

  • Known sensitivity to any of the test material ingredients.
  • Routine high dosage use of anti-inflammatory medications (aspirin, ibuprofen, corticosteroids), immunosuppressive drugs or antihistamine medications (steroid nose drops and/or eye drops are permitted) (one-8lmg or 325mg aspirin okay) (birth control is okay but needs to be reported).
  • Use of topical OTC/Rx drugs or other cosmetics at the test sites.
  • Immunological disorders such as HIV positive and systemic lupus erythematosus (interview only)
  • Participation in any clinical study within the last four weeks.
  • Pregnant or lactating women (interview only).
  • Damaged skin in or around test sites (including sunburn, uneven skin tones, tattoos, scars or other disfiguration of the test site).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00991198

Locations
United States, North Carolina
Dermatology Consultants Inc
High Point, North Carolina, United States, 27262
Sponsors and Collaborators
Aria Aesthetics Inc.
Investigators
Principal Investigator: Zoe D Draelos, MD Dermatology Consultants Inc.
  More Information

No publications provided

Responsible Party: Larry Rheins, PhD/President, Aria Aesthetics, Inc.
ClinicalTrials.gov Identifier: NCT00991198     History of Changes
Other Study ID Numbers: IFLOTDO002
Study First Received: October 6, 2009
Last Updated: June 6, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Aria Aesthetics Inc.:
Topically dissolved oxygen
inflammatory cutaneous disease
rosacea
acne vulgaris
atopic dermatitis
seborrheic dermatitis
photodamage

Additional relevant MeSH terms:
Dermatitis
Dermatitis, Atopic
Acne Vulgaris
Rosacea
Dermatitis, Seborrheic
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Acneiform Eruptions
Facial Dermatoses
Sebaceous Gland Diseases
Skin Diseases, Papulosquamous

ClinicalTrials.gov processed this record on October 02, 2014